AWHL at a glance
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
AWHL price history
Loading recent earnings…
Investment thesis
What must happen next
Physician and payer acceptance of Aspira's noninvasive AI-powered gynecologic tests must move from niche use into routine ovarian-cancer risk-assessment workflows; otherwise the platform cannot create durable operating leverage.WeakeningMateriality: High
The company profile describes Aspira as dedicated to discovery, development, and commercialization of noninvasive, AI-powered tests to aid diagnosis of gynecologic diseases, starting with ovarian cancer. If adoption broadens, small fixed-cost leverage can matter; if it does not, the company remains a subscale lab with limited strategic value.
Watch: Major commercial payers or Medicare contractors restrict coverage because the tests are not viewed as changing clinical management.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
The company profile describes Aspira as dedicated to discovery, development, and commercialization of noninvasive, AI-powered tests to aid diagnosis of.
Open source ↗Reimbursement quality, test mix, and lab-cost control can support attractive incremental economics, so added sample volume should contribute meaningfully to gross profit if demand appears.StrengtheningMateriality: High
GAAP annual gross profit rose from $5.262 million in FY2023 to $5.479 million in FY2024 and $5.915 million in FY2025 while revenue was nearly flat. This determines whether growth would be valuable or merely consume more cash.
Watch: Medicare or commercial payer reimbursement cuts lower revenue per test.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual gross profit rose from $5.262 million in FY2023 to $5.479 million in FY2024 and $5.915 million in FY2025.
Open source ↗Management's expense reset has lowered the revenue needed for breakeven, but the model only works if commercialization can scale without rebuilding a cash-intensive sales and R&D footprint.StrengtheningMateriality: Medium
GAAP annual operating loss narrowed from $31.138 million in FY2022 to $18.852 million in FY2023, $16.278 million in FY2024, and $7.913 million in FY2025. Operating leverage is the bridge from diagnostic adoption to shareholder value; if growth requires heavy spending, gross-profit gains will not reach owners.
Watch: Broad OB/GYN adoption requires a much larger direct sales force than the current organization can support.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating loss narrowed from $31.138 million in FY2022 to $18.852 million in FY2023, $16.278 million in FY2024, and.
Open source ↗Financing capacity is a core constraint on shareholder value because Aspira must bridge ongoing operating cash burn from a very small cash balance and negative book equity.StrengtheningMateriality: Medium
Cash was $1.755 million at FY2025 year-end. Even if the product thesis is right, common shareholders can lose if survival requires highly dilutive capital.
Watch: A strategic partner funds commercialization or clinical validation on nondilutive terms.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $1.755 million at FY2025 year-end.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Physician and payer acceptance of Aspira's noninvasive AI-powered gynecologic tests must move from niche use into routine ovarian-cancer risk-assessment workflows; otherwise the platform cannot create durable operating leverage. If adoption broadens, small fixed-cost leverage can matter; if it does not, the company remains a subscale lab with limited strategic value.
Reimbursement quality, test mix, and lab-cost control can support attractive incremental economics, so added sample volume should contribute meaningfully to gross profit if demand appears. This determines whether growth would be valuable or merely consume more cash.
Management's expense reset has lowered the revenue needed for breakeven, but the model only works if commercialization can scale without rebuilding a cash-intensive sales and R&D footprint. Operating leverage is the bridge from diagnostic adoption to shareholder value; if growth requires heavy spending, gross-profit gains will not reach owners.
Financing capacity is a core constraint on shareholder value because Aspira must bridge ongoing operating cash burn from a very small cash balance and negative book equity. Even if the product thesis is right, common shareholders can lose if survival requires highly dilutive capital.
All standing thesis claims
Original report summary
payer and physician adoption accelerates before financing needs dilute shareholders.
Bull case and bear case
Bull case and bear case for Aspira Women's Health
Where the evidence on Aspira Women's Health disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 4 thesis points, 3 strengthening and 1 weakening.
Bull case: what the evidence supports
Reimbursement quality, test mix, and lab-cost control can support attractive incremental economics, so added sample volume should contribute meaningfully to gross profit if demand appears.
Management's expense reset has lowered the revenue needed for breakeven, but the model only works if commercialization can scale without rebuilding a cash-intensive sales and R&D footprint.
Financing capacity is a core constraint on shareholder value because Aspira must bridge ongoing operating cash burn from a very small cash balance and negative book equity.
Bear case: what the evidence questions
Physician and payer acceptance of Aspira's noninvasive AI-powered gynecologic tests must move from niche use into routine ovarian-cancer risk-assessment workflows; otherwise the platform cannot create durable operating leverage.
Thesis-Break Engine
What has broken in Aspira Women's Health’s thesis
Each break OptimistFi flagged on Aspira Women's Health, dated — with what has historically followed the same kind of break across the market, not a forecast for Aspira Women's Health.
- Financial restatementcondition set before this filing
Across all companies, this kind of break has happened 793 times before. Those stocks trailed comparable companies by a median of 5% over the next six months, and 44% of them trailed it by 10 points or more.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedEntered a material definitive agreement.
Aspira Women's Health filed an SEC 8-K on 2026-07-15: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Aspira Women's Health filed an SEC 8-K on 2026-06-22: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Aspira Women's Health filed an SEC 8-K on 2026-06-09: Entered a material definitive agreement. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- Major commercial payers or Medicare contractors restrict coverage because the tests are not viewed as changing clinical management.
- Medicare or commercial payer reimbursement cuts lower revenue per test.
- Broad OB/GYN adoption requires a much larger direct sales force than the current organization can support.
- A strategic partner funds commercialization or clinical validation on nondilutive terms.
AWHL news
Loading headlines…
Financial statements
AWHL income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
AWHL: quick answers
- What is AWHL's short interest?
- As of October 30, 2026, 7,285 AWHL shares were sold short, up 35.1% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. AWHL short interest history

